# Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

> **NCT04813406** · NA · UNKNOWN · sponsor: **Henan Provincial People's Hospital** · enrollment: 53 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Anlotinib + Sintilimab

## Key facts

- **NCT ID:** NCT04813406
- **Lead sponsor:** Henan Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03
- **Primary completion:** 2022-01
- **Final completion:** 2022-01
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2021-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04813406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04813406, "Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04813406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*